Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

Inclusion Criteria:

• Locally advanced non-operable or metastatic solid tumor, except for skin cancer

• Eligible for routine (standard) treatment with immune checkpoint inhibitor (+/-chemo/targeted therapy) as per the discretion of the local investigator

• Subjects must be eligible for treatment with mistletoe preparations (controlledbrain metastases, prednisolone equivalent below 10mg, no known hypersensitivity)

• ECOG (Eastern Cooperative Oncology Group) performance status score of 0-2

• Males and Females at least 18 years of age; no subjects under tutelage

• No previous mistletoe treatment

Exclusion Criteria:

• Contraindications to Iscador® Qu or immune checkpoint inhibitors, e.g.hypersensitivity, active autoimmune disorder

• Patients with skin cancer

• Participation in another study with investigational drug within 30 days prior toenrolment (participation in observational studies or diagnostic studies without aparticular drug intervention are allowed)

• Enrolment of the investigator, his/her family members, employees and other dependent